

Business Consortium

 Mission of AABC

The mission of the Alzheimer's Association Business Consortium (AABC) is to advance Alzheimer's disease research and innovation in small- and medium-size biotechnology, diagnostics, medical device and contract research organizations.

AABC members work in areas of common interest pre-competitively to advance both the field of Alzheimer's research and the goals of its member organizations. They provide leadership and direction to the group's areas of focus, which include, but are not limited to, collaborations, recognition and visibility, and knowledge and information sharing. AABC welcomes new members who are aligned in their commitment to research and innovation. To express interest in joining, please email [Joseph Araujo](#), [Dr. Codi Gharagouzloo](#), co-chairs, or [Dr. Christopher Weber](#), facilitator.

 Congratulations to the New AABC Co-Chair

Congratulations to Dr. Codi Gharagouzloo, who was elected as the new AABC co-chair for a two-year term. Dr. Gharagouzloo is the scientific founder and CEO of [Imaginostics](#), a health tech startup developing breakthrough diagnostics for Alzheimer's disease and other dementias. We are delighted to have him serving in this role.

The Alzheimer's Association extends its gratitude to Dr. Judy Walker for her service to AABC. Under her leadership, AABC has grown in membership and hosted events that have advanced our mission. We would also like to thank our other co-chair candidates, Michael Fossel of [Telocyte](#) and CJ Barnum of [INmune Bio, Inc.](#) We know they will provide important leadership contributions to AABC.

We look forward to working with the two co-chairs, Mr. Araujo and Dr. Gharagouzloo, in the upcoming year, and would like to thank everyone for their continued participation.

 Welcome to our New Members

AABC is growing! Welcome to:

- » **Rashmi Joshi, [Asha AI](#).** Asha AI is a conversational remote care solution that empowers elders to age in place, and keeps their caregiving family members connected and informed.
- » **CJ Barnum and David Moss, INmune Bio, Inc.** INmune Bio, Inc., is focused on modulating components of the innate immune system to activate an immune response against cancer and Alzheimer's disease.

 News from AABC Members**Neuronascent Announces Publication of Pre-clinical Results of Alzheimer's Disease Clinical Candidate, NNI-362.**

Neuronascent is a clinical stage company founded to discover and develop novel therapies to halt and/or reverse diseases of the central nervous system by promoting true neuron regeneration. The short report in the Stem Cell Research & Therapy journal, "[Novel pharmacotherapy: NNI-362, an allosteric p70S6 kinase stimulator, reverses cognitive and neural regenerative deficits in models of aging and disease.](#)" describes the phenotypic screen used by Neuronascent to discover NNI-362 and details the *in vitro* and *in vivo* results of this NCE.

This small molecule therapy is presently in Phase 1a clinical trial for mild to moderate Alzheimer's disease, which is supported by a NIA R01 grant in healthy-aged volunteers. The unique mechanism-of-action of NNI-362 targeting an allosteric auto-inhibitory site allows for selective neuron generation in age-related degenerative disorders and aims to be the first disease-modifying and potentially "curative" therapy for diseases such as Alzheimer's.



DiamiR Receives USPTO Notice of Allowance For Key Patent Covering the Use of microRNA Biomarkers from Bodily Fluids for Diagnosis and Monitoring of Rett Syndrome and Other Neurodevelopmental Diseases

DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, announced that it has received a notice of allowance from the United States Patent & Trademark Office (USPTO) for U.S. Patent Application No. 16/028,206 entitled, "Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders." The patent covers the use of methods developed by DiamiR based on targeted quantitative analysis of microRNAs enriched in the brain and other affected organs and detectable in blood plasma as biomarkers of Rett syndrome and other neurodevelopmental diseases.

"Allowance of this key new patent by the USPTO further strengthens DiamiR's global IP portfolio focused on early detection, differential diagnosis, prediction of progression and monitoring of brain health and other conditions," said Dr. Samuil Umansky, president and chief scientific officer of DiamiR. "In DiamiR's ongoing clinical biomarker program for Rett syndrome, our main objective is to provide researchers and clinicians with minimally invasive, accurate molecular solutions for evaluating and monitoring disease severity and progression as well as response to treatment during drug development."



Virtual Events

Continuing to Serve Small Businesses During the Pandemic

[The National Institute on Aging Office of Small Business Research \(OSBR\)](#) is adapting and working hard to support small companies, entrepreneurship and innovation during the COVID-19 pandemic.

The NIA OSBR offers opportunities to connect and learn about small business funding. Follow them on [LinkedIn](#) for additional networking opportunities for grantees and investors.

Latinos & Alzheimer's Symposium

Virtually attend the Alzheimer's Association [Latinos & Alzheimer's Symposium](#), May 20-21, 2021 to address the disparities in dementia risk, early detection and care in the Latino/Hispanic population — at no cost. Now in its second year, the symposium offers opportunities to collaborate with researchers and health care professionals and attend mentoring and networking events.

[Register today.](#)

Alzheimer's Association International Conference® (AAIC®) Satellite Symposium Athens

[Register today](#) and join leaders in the field at the virtual AAIC Satellite Symposium, May 12-13, 2021 to discuss the latest findings and explore emerging dementia research and ideas in the Mediterranean region — at no cost.

[Submit an abstract](#) for the virtual AAIC Satellite Symposium by March 17. Submissions will be considered for a virtual poster presentation, as well as a special opportunity to present a Lightning Session — a four-minute-or-less presentation designed to give the audience a snapshot of your work.

Addressing Health Disparities

[Promoting Diverse Perspectives: Addressing Health Disparities Related to Alzheimer's and all Dementias](#) is a free virtual conference — June 14-16, 2021 — to support vital health equity research and drive collaboration across the dementia science field. [Register today](#) to learn about related developments in the scientific community and take advantage of networking and mentorship opportunities.

Health disparities researchers are invited to [submit an abstract](#) by April 22 for a presentation at the Addressing Health Disparities conference. Share your findings on research themes within the NIA Health Disparities Research Framework determinants, including Environmental, Social, Behavioral, and/or Biological.

>> AAIC 2021 Developing Topics

Get ready to submit your [late-breaking findings](#) for a chance to present at the [AAIC 2021](#), July 26-30 in Amsterdam, Netherlands or online. Developing Topics abstract submissions open on April 12 and will be accepted through May 12.

Criteria for acceptance:

- » Quality of scientific research.
- » Relevance to Alzheimer's and other dementias.
- » Newness of information — abstracts related to COVID-19 are encouraged.
- » Potential impact on the field.

[Learn more.](#)

i Past Events

AABC Investment Webinar

On November 18, 2020, AABC hosted a virtual investment webinar, connecting investors with our membership. The webinar featured presentations from Dr. Stacie Weninger, FBRI president, Dr. Beth Shafer, head of Neuroscience Business Development at Takeda Pharmaceuticals, and Dr. Christa Studzinski, partnerships manager at the Ontario Brain Institute. The panel was an exciting opportunity for our presenters and AABC membership to discuss finance, collaboration, and partnerships in research from an investor's perspective.

in Social Media

Join our new [LinkedIn](#) page! As discussed during the AAIC AABC meeting, please visit the page and request to join. We look forward to using the page to foster partnerships and communications.

Alzheimer's Association Science Hub App



Science Hub provides the latest news right in the palm of your hand. This trusted tool distributes research, spreads awareness and delivers accurate information directly to your phone.

Learn more at alz.org/sciencehub, or search “Science Hub” in your app store.

Spread the Word

To help us grow AABC, please continue to introduce new members and companies to our group. We also welcome ideas or events for this newsletter so we can better serve you. Please send your suggestions to [Ashley Hansen](#).